NeoGenomics (NEO): Losses Widen, Profitability Still Elusive as Revenue Trails Market Growth [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
Revenue is expected to grow at 8.7% per year, a pace trailing the broader US market's projected 10.2% annual growth. Despite a more favorable Price-to-Sales ratio of 1.9x compared to its peers at 2.6x, the stock remains more expensive than the wider US healthcare industry average of 1.3x. Investors face a lingering risk tied to the company's ongoing unprofitability. See our full analysis for NeoGenomics. Now, we will see how these headline numbers compare with the most widely held market narratives for NeoGenomics, examining which stories hold up and which expectations might need rethinking. See what the community is saying about NeoGenomics NasdaqCM:NEO Earnings & Revenue History as at Oct 2025 Profit Margins Still in Negative Territory Profit margins remain below zero, with analysts estimating a shift from -15.1% now to only 5.4% (industry average) by 2028 if everything goes to plan. Analysts' consensus view highlights that NeoGenomics' road to profitability relies on
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) [Yahoo! Finance]Yahoo! Finance
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- 1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 10/28/25 - Beat
NEO
Sec Filings
- 12/3/25 - Form 4
- 12/2/25 - Form SCHEDULE
- 11/28/25 - Form 4
- NEO's page on the SEC website